Table 2 Demographics and baseline characteristics
Baseline characteristics | Pediatric patients (N = 241) |
|---|---|
Age, years | |
Mean (s.d.) | 6.3 (4.9) |
Median (range) | 5.0 (<1.0–17.0) |
Age stratification, years, n (%) | |
<2 | 61 (25.3) |
2 to <6 | 63 (26.1) |
6 to <12 | 72 (29.9) |
12 to <18 | 45 (18.7) |
Gender, n (%) | |
Male | 159 (66.0) |
Female | 82 (34.0) |
Stem cell source, n (%) | |
BM | 116 (48.1) |
PBSC | 92 (38.2) |
Cord blood unit(s) | 33 (13.7) |
Donor typea, n (%) | |
Matched unrelated | 100 (41.5) |
Haploidentical | 49 (20.3) |
Mismatchedb | 43 (17.8) |
Cord blood unit(s) | 35 (14.5) |
Matched related | 33 (13.7) |
T-cell depletionc, n (%) | |
ATG | 95 (39.4) |
Alemtuzumab (Campath) | 62 (25.7) |
Ex vivo | 53 (22.0) |
None | 31 (12.9) |
Time from AdV infection to AdV ≥ 1000 copies/ml, days | |
Mean (s.d.) | 15.2 (24.5) |
Median (range) | 7 (0.0–146.0) |
IQR | 0.0–17.0 |
<28 days, n (%) | 201 (83.4) |
≥28 days, n (%) | 40 (16.6) |
Time from allo-HCT to AdV ≥ 1000 copies/ml, days | |
Mean (s.d.) | 40.4 (38.8) |
Median (range) | 26.0 (0.0–174.0) |
IQR | 13.0–56.0 |
<28 days, n (%) | 130 (53.9) |
≥28 days, n (%) | 111 (46.1) |
Disease for which allo-HCT was conducted, n (%) | |
Malignant | 148 (61.4) |
Nonmalignant immunodeficient | 72 (29.9) |
Nonmalignant immunocompetent | 21 (8.7) |
dsDNA viral coinfections, n (%) | |
None | 138 (57.3) |
≥1 dsDNA viral infection in addition to AdV | 103 (42.7) |
Comorbiditiesd, n (%) | |
None | 147 (61.0) |
≥1 | 94 (39.0) |
Lymphocyte count at time of AdV viremia ≥ 1000 copies/ml, n (%) | |
≥900 | 14 (5.8) |
300–899 | 35 (14.5) |
<300 | 192 (79.7) |
Maximum stage GvHD among skin, liver, GI at the time of AdV viremia ≥ 1000 copies/ml, n (%) | |
0 | 174 (72.2) |
1 | 22 (9.1) |
2 | 17 (7.1) |
3 | 16 (6.6) |
4 | 12 (5.0) |
